Recurrent Lymphoplasmacytic Lymphoma

12 clinical trials · Condition

Record	Firm	Date
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma (NCT04578600)	Joseph Tuscano	2020-10-23
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (NCT03479268)	City of Hope Medical Center	2018-04-27
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas (NCT03277729)	Fred Hutchinson Cancer Center	2017-12-05
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT02950220)	Kami Maddocks	2017-01-12
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas (NCT02332980)	Mayo Clinic	2015-02-19
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (NCT02153580)	City of Hope Medical Center	2014-09-24
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NCT01955499)	National Cancer Institute (NCI)	2013-09-24
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer (NCT00723099)	Fred Hutchinson Cancer Center	2008-06-25

Every clearance here is in the API, with alerts when new ones post.